Last 12 months
Inside the activity.
0 purchase rows · 35 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 16 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 17 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2022 Filed May 4, 2022 21:54 UTC |
Litchfield CarolineEVP & CFO
|
Exercise / conversionRestricted Stock Unit · Derivative | 773 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013286 · form4.xml · derivative · entry 3 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 773 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:54 UTC |
Litchfield CarolineEVP & CFO
|
Tax withholdingCommon Stock | 373 | $87.65 | $32,693.45 |
DisclosureSEC source: 0001127602-22-013286 · form4.xml · nonDerivative · entry 2 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,426.2881 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:54 UTC |
Litchfield CarolineEVP & CFO
|
Exercise / conversionCommon Stock | 773 | $87.65 | $67,753.45 |
DisclosureSEC source: 0001127602-22-013286 · form4.xml · nonDerivative · entry 1 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,799.2881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:58 UTC |
LeCointe-Cephas LisaSVP Chief Ethics & Com Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 452 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013291 · form4.xml · derivative · entry 3 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 452 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:58 UTC |
LeCointe-Cephas LisaSVP Chief Ethics & Com Officer
|
Tax withholdingCommon Stock | 155 | $87.65 | $13,585.75 |
DisclosureSEC source: 0001127602-22-013291 · form4.xml · nonDerivative · entry 2 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,129.781 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:58 UTC |
LeCointe-Cephas LisaSVP Chief Ethics & Com Officer
|
Exercise / conversionCommon Stock | 452 | $87.65 | $39,617.80 |
DisclosureSEC source: 0001127602-22-013291 · form4.xml · nonDerivative · entry 1 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,284.781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 5, 2022 20:53 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
GrantRestricted Stock Unit · Derivative | 28,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013508 · form4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,703 Underlying: Common Stock · 28,703 shares Expires 2023-05-03 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest in full and are distributed as shares of Merck & Co., Inc. common stock on 5/3/2023. Read SEC document |
| May 03, 2022 Filed May 5, 2022 20:55 UTC |
Davis Robert MDirector · CEO & President
|
GrantStock Option (Right to Buy) · Derivative | 228,155 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013510 · form4.xml · derivative · entry 2 Davis Robert M · CIK 0001363076 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,155 Underlying: Common Stock · 228,155 shares Expires 2032-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 20:57 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
GrantStock Option (Right to Buy) · Derivative | 58,252 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013512 · form4.xml · derivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,252 Underlying: Common Stock · 58,252 shares Expires 2032-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 20:59 UTC |
Downing Cristal NChief Comm. & Public Afrs Ofcr
|
GrantStock Option (Right to Buy) · Derivative | 19,417 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013514 · form4.xml · derivative · entry 1 Downing Cristal N · CIK 0001879216 · Chief Comm. & Public Afrs Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,417 Underlying: Common Stock · 19,417 shares Expires 2032-05-02 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:01 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
GrantStock Option (Right to Buy) · Derivative | 58,252 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013516 · form4.xml · derivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,252 Underlying: Common Stock · 58,252 shares Expires 2032-05-02 F3 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:04 UTC |
LeCointe-Cephas LisaSVP Chief Ethics & Com Officer
|
GrantRestricted Stock Unit · Derivative | 2,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013519 · form4.xml · derivative · entry 4 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,067 Underlying: Common Stock · 2,067 shares Expires 2025-05-03 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:04 UTC |
LeCointe-Cephas LisaSVP Chief Ethics & Com Officer
|
GrantStock Option (Right to Buy) · Derivative | 11,650 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013519 · form4.xml · derivative · entry 3 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,650 Underlying: Common Stock · 11,650 shares Expires 2032-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:07 UTC |
Klobuchar Michael AEVP - Chief Strategy Officer
|
GrantStock Option (Right to Buy) · Derivative | 25,243 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013522 · form4.xml · derivative · entry 8 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,243 Underlying: Common Stock · 25,243 shares Expires 2032-05-02 F5 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:09 UTC |
Litchfield CarolineEVP & CFO
|
GrantStock Option (Right to Buy) · Derivative | 53,398 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013524 · form4.xml · derivative · entry 2 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,398 Underlying: Common Stock · 53,398 shares Expires 2032-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:11 UTC |
Li Dean YExecutive VP & President, MRL
|
GrantStock Option (Right to Buy) · Derivative | 75,728 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013527 · form4.xml · derivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,728 Underlying: Common Stock · 75,728 shares Expires 2032-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:17 UTC |
Zachary JenniferEVP, General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 58,252 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013533 · form4.xml · derivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,252 Underlying: Common Stock · 58,252 shares Expires 2032-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:13 UTC |
MIZELL STEVENEVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 40,777 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013530 · form4.xml · derivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,777 Underlying: Common Stock · 40,777 shares Expires 2032-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:19 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
GrantRestricted Stock Unit · Derivative | 2,411 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013535 · form4.xml · derivative · entry 4 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,411 Underlying: Common Stock · 2,411 shares Expires 2025-05-03 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:19 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
GrantStock Option (Right to Buy) · Derivative | 13,592 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013535 · form4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,592 Underlying: Common Stock · 13,592 shares Expires 2032-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:21 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
GrantStock Option (Right to Buy) · Derivative | 21,359 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013539 · form4.xml · derivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,359 Underlying: Common Stock · 21,359 shares Expires 2032-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:24 UTC |
Garay ArpaSVP Human Health Global Mktg.
|
GrantStock Option (Right to Buy) · Derivative | 21,359 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013544 · form4.xml · derivative · entry 4 Garay Arpa · CIK 0001916360 · SVP Human Health Global Mktg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,359 Underlying: Common Stock · 21,359 shares Expires 2032-05-02 F4 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:27 UTC |
Oosthuizen Johannes JacobusSVP, U.S. Market
|
GrantStock Option (Right to Buy) · Derivative | 21,359 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013549 · form4.xml · derivative · entry 4 Oosthuizen Johannes Jacobus · CIK 0001916310 · SVP, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,359 Underlying: Common Stock · 21,359 shares Expires 2032-05-02 F4 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:11 UTC |
Garay ArpaSVP Human Health Global Mktg.
|
Exercise / conversionRestricted Stock Unit · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013015 · form4.xml · derivative · entry 3 Garay Arpa · CIK 0001916360 · SVP Human Health Global Mktg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866 Underlying: Common Stock · 866 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:11 UTC |
Garay ArpaSVP Human Health Global Mktg.
|
Tax withholdingCommon Stock | 247 | $88.69 | $21,906.43 |
DisclosureSEC source: 0001127602-22-013015 · form4.xml · nonDerivative · entry 2 Garay Arpa · CIK 0001916360 · SVP Human Health Global Mktg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 909 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:11 UTC |
Garay ArpaSVP Human Health Global Mktg.
|
Exercise / conversionCommon Stock | 866 | $88.69 | $76,805.54 |
DisclosureSEC source: 0001127602-22-013015 · form4.xml · nonDerivative · entry 1 Garay Arpa · CIK 0001916360 · SVP Human Health Global Mktg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:13 UTC |
Klobuchar Michael AEVP - Chief Strategy Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013019 · form4.xml · derivative · entry 7 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866 Underlying: Common Stock · 866 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:13 UTC |
Klobuchar Michael AEVP - Chief Strategy Officer
|
Tax withholdingCommon Stock | 427 | $88.69 | $37,870.63 |
DisclosureSEC source: 0001127602-22-013019 · form4.xml · nonDerivative · entry 2 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,497.93 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:13 UTC |
Klobuchar Michael AEVP - Chief Strategy Officer
|
Exercise / conversionCommon Stock | 866 | $88.69 | $76,805.54 |
DisclosureSEC source: 0001127602-22-013019 · form4.xml · nonDerivative · entry 1 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,924.93 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:16 UTC |
Oosthuizen Johannes JacobusSVP, U.S. Market
|
Exercise / conversionRestricted Stock Unit · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013022 · form4.xml · derivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · SVP, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866 Underlying: Common Stock · 866 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:16 UTC |
Oosthuizen Johannes JacobusSVP, U.S. Market
|
Tax withholdingCommon Stock | 427 | $88.69 | $37,870.63 |
DisclosureSEC source: 0001127602-22-013022 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · SVP, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,661.881 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:16 UTC |
Oosthuizen Johannes JacobusSVP, U.S. Market
|
Exercise / conversionCommon Stock | 866 | $88.69 | $76,805.54 |
DisclosureSEC source: 0001127602-22-013022 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · SVP, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,088.881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:17 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
Exercise / conversionRestricted Stock Unit · Derivative | 928 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013024 · form4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 930 Underlying: Common Stock · 928 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F3 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:17 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
Tax withholdingCommon Stock | 318 | $88.69 | $28,203.42 |
DisclosureSEC source: 0001127602-22-013024 · form4.xml · nonDerivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,886.972 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:17 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
Exercise / conversionCommon Stock | 928 | $88.69 | $82,304.32 |
DisclosureSEC source: 0001127602-22-013024 · form4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,204.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:19 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 577 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013026 · form4.xml · derivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 577 Underlying: Common Stock · 577 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F3 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:19 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
Tax withholdingCommon Stock | 198 | $88.69 | $17,560.62 |
DisclosureSEC source: 0001127602-22-013026 · form4.xml · nonDerivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,982.757 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:19 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
Exercise / conversionCommon Stock | 577 | $88.69 | $51,174.13 |
DisclosureSEC source: 0001127602-22-013026 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,180.757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:21 UTC |
Li Dean YExecutive VP & President, MRL
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013028 · form4.xml · derivative · entry 3 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062 Underlying: Common Stock · 1,061 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F3 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:21 UTC |
Li Dean YExecutive VP & President, MRL
|
Tax withholdingCommon Stock | 523 | $88.69 | $46,384.87 |
DisclosureSEC source: 0001127602-22-013028 · form4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,065.945 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:21 UTC |
Li Dean YExecutive VP & President, MRL
|
Exercise / conversionCommon Stock | 1,061 | $88.69 | $94,100.09 |
DisclosureSEC source: 0001127602-22-013028 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,588.945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:22 UTC |
Litchfield CarolineEVP & CFO
|
Exercise / conversionRestricted Stock Unit · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013030 · form4.xml · derivative · entry 3 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866 Underlying: Common Stock · 866 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F3 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:22 UTC |
Litchfield CarolineEVP & CFO
|
Tax withholdingCommon Stock | 427 | $88.69 | $37,870.63 |
DisclosureSEC source: 0001127602-22-013030 · form4.xml · nonDerivative · entry 2 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,026.2881 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:22 UTC |
Litchfield CarolineEVP & CFO
|
Exercise / conversionCommon Stock | 866 | $88.69 | $76,805.54 |
DisclosureSEC source: 0001127602-22-013030 · form4.xml · nonDerivative · entry 1 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,453.2881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:25 UTC |
LeCointe-Cephas LisaSVP Chief Ethics & Com Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 640 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013032 · form4.xml · derivative · entry 3 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643 Underlying: Common Stock · 640 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F3 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:25 UTC |
LeCointe-Cephas LisaSVP Chief Ethics & Com Officer
|
Tax withholdingCommon Stock | 220 | $88.69 | $19,511.80 |
DisclosureSEC source: 0001127602-22-013032 · form4.xml · nonDerivative · entry 2 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,832.781 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:25 UTC |
LeCointe-Cephas LisaSVP Chief Ethics & Com Officer
|
Exercise / conversionCommon Stock | 640 | $88.69 | $56,761.60 |
DisclosureSEC source: 0001127602-22-013032 · form4.xml · nonDerivative · entry 1 LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,052.781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 17:35 UTC |
Coe Mary EllenDirector
|
GrantPhantom Stock · Derivative | 396.0999 | $82.05 | $32,500.00 |
DisclosureSEC source: 0001127602-22-010791 · form4.xml · derivative · entry 2 Coe Mary Ellen · CIK 0001691304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,344.789 Underlying: Common Stock · 396.0999 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 17:38 UTC |
GLOCER THOMAS HDirector
|
GrantPhantom Stock · Derivative | 137.1115 | $82.05 | $11,250.00 |
DisclosureSEC source: 0001127602-22-010793 · form4.xml · derivative · entry 2 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,714.6991 Underlying: Common Stock · 137.1115 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 17:39 UTC |
Seidman Christine EDirector
|
GrantPhantom Stock · Derivative | 198.05 | $82.05 | $16,250.00 |
DisclosureSEC source: 0001127602-22-010795 · form4.xml · derivative · entry 2 Seidman Christine E · CIK 0001805745 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,362.2803 Underlying: Common Stock · 198.05 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.